q3 adjusted operating earnings per share $2.98.
qtrly adjusted operating loss per share $0.12.
qtrly net sales of $2.8 billion, up 52% year-over-year.
sees q4 term life margin in range of 19% to 20%.
sees fy sales to be about 10% above pre-pandemic levels.
sees q4 investment sales to grow between 20% and 25% year over year.
sees q4 sales down 13% to 15%.
compname reports q3 earnings per share of $0.19.
expects to surpass $900 billion of face amount in force by end of year.
qtrly net inflows of $1 billion were well above historical levels.
compname reports fourth quarter and full year 2021 results and announces financial results.
qtrly total face amount of $894 billion, up 6% year-over-year.
expect q4 approved policy levels to be about 36,000 to 40,000, or approximately double q3 levels.
expect negative cash flow to decline over time and approach breakeven in about 6 years.
expect strong persistency to continue lapses that are 20% to 25% lower than pre-pandemic levels across all durations except duration 1, where lapses are expected to be about 15% lower.
compname reports q3 sales up more than 50% year over year.
